Identification of key genes involved in tumor immune cell infiltration and cetuximab resistance in colorectal cancer. [PDF]
Cancer Cell Int, 2021 The anti-epidermal growth factor receptor (EGFR) antibody introduces adaptable variations to the transcriptome and triggers tumor immune infiltration, resulting in colorectal cancer (CRC) treatment resistance.
Liang L +9 more
europepmc +2 more sources
Signal Transduction and Targeted Therapy, 2022 Cetuximab is a widely used drug for treating head and neck squamous cell carcinomas (HNSCCs); however, it provides restricted clinical benefits, and its response duration is limited by drug resistance.
Qi Wu, Zhiyuan Zhang, Shuyang Sun
exaly +2 more sources
Predictive role of UCA1-containing exosomes in cetuximab-resistant colorectal cancer [PDF]
Cancer Cell International, 2018 Background Primary or acquired resistance to cetuximab often occurs during targeted therapy in metastatic colorectal cancer (mCRC) patients. In many cancers, the key role of the long noncoding RNA (lncRNA) urothelial carcinoma-associated 1 (UCA1) in ...
Ying-nan Yang +8 more
doaj +3 more sources
Cancer Cell International, 2020 Background Long noncoding RNAs (lncRNAs) have been shown to participate in multiple biological processes and confer drug resistance. However, it remains unclear whether lncRNAs are involved in conferring cetuximab resistance in colorectal cancer (CRC ...
Xiaoqian Zhang +10 more
doaj +2 more sources
Mechanisms of Cetuximab Resistance and How to Overcome It [PDF]
Critical Issues in Head and Neck Oncology, 2021 Deregulated or increased signalling of the epidermal growth factor receptor (EGFR) plays an integral role in the development of various cancer types, including head and neck squamous cell carcinoma (HNSCC), making it a compelling drug target.
I. D. Pauw, Carolien Boeckx, A. Wouters
semanticscholar +2 more sources
Berberine: a promising strategy to combat cetuximab-resistance in colorectal cancer [PDF]
BMC CancerCetuximab, a monoclonal antibody against epidermal growth factor receptor (EGFR), is approved as a front-line treatment for metastatic colorectal cancers, but limited efficacy is obtained.
Jianmin Ye +6 more
doaj +2 more sources
Cetuximab Induces Eme1-Mediated DNA Repair: a Novel Mechanism for Cetuximab Resistance
Neoplasia: An International Journal for Oncology Research, 2014 Overexpression of the epidermal growth factor receptor (EGFR) is observed in a large number of neoplasms. The monoclonal antibody cetuximab/Erbitux is frequently applied to treat EGFR-expressing tumors.
Agnieszka Weinandy +11 more
doaj +4 more sources
Pathway-Specific Genome Editing of PI3K/mTOR Tumor Suppressor Genes Reveals that PTEN Loss Contributes to Cetuximab Resistance in Head and Neck Cancer. [PDF]
Mol Cancer Ther, 2020 Cetuximab, an mAb targeting EGFR, is a standard of care for the treatment for locally advanced or metastatic head and neck squamous cell carcinoma (HNSCC).
Izumi H +9 more
europepmc +2 more sources
MLH1 Deficiency Induces Cetuximab Resistance in Colon Cancer via Her-2/PI3K/AKT Signaling. [PDF]
Adv Sci (Weinh), 2020 The rapid onset of resistance to cetuximab (CTX) limits its clinical utility in colorectal cancer (CRC) patients. This study aims to understand a potential role of mismatch repair gene mutL homolog 1 (MLH1) in CTX response. Functional analysis of MLH1 in
Han Y +13 more
europepmc +2 more sources
miR-302a Inhibits Metastasis and Cetuximab Resistance in Colorectal Cancer by Targeting NFIB and CD44. [PDF]
Theranostics, 2019 Introduction: Metastasis and drug resistance contribute substantially to the poor prognosis of colorectal cancer (CRC) patients. However, the epigenetic regulatory mechanisms by which CRC develops metastatic and drug-resistant characteristics remain ...
Sun L +19 more
europepmc +2 more sources